Sign in
Stories
Aptorum Group Limited Reports Financial Results and Business Update
Share
AptarGroup: Sustaining Excellence
Aptiv PLC Reports Record 2023 Financial ...
Aptiv to Release Q4 2023 Financial Resul...
4P-Pharma Secures €15 Million Funding
Acquisition Progress Amid Safety Concern
Afya Limited Expands Medical Seats in Br...
Overview
API
Aptorum Group Limited reported financial results and provided a business update for the six-month period ended June 30, 2023. The company is focused on advancing its therapeutic programs in oncology, autoimmune, and infectious diseases. It completed Pre-IND discussions with the US FDA for ALS-4 and submitted a Phase 1b/2a clinical trial protocol of SACT-1 to US FDA. The company also entered into a non-binding Letter of Intent and Term Sheet to merge its subsidiary with Universal Sequencing Technology Corporation. Additionally, the company raised approximately $1,625,745 in gross proceeds through an ATM program and announced the resignations of key personnel.
Ask a question
How might the merger with Universal Sequencing Technology Corporation impact Aptorum Group Limited's future prospects?
What are the potential implications of the completed Pre-IND discussions with the US FDA for ALS-4?
What factors contributed to the resignations of key personnel?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Sep 2023
Oct 2023
Nov 2023
Coverage